INAVA
INAVA (innate immunity activator, also known as C1orf106 and FLJ10901) is a nuclear and cytoplasmic protein that supports pattern recognition receptor signalling and cytokine secretion in myeloid cells. It also helps stabilise adherens junctions in the intestine. Browse Assay Genie's current range of INAVA research reagents below, or read on for the biology behind the target.
INAVA is expressed in peripheral macrophages and intestinal myeloid-derived cells. It is required for optimal signalling downstream of pattern recognition receptors (PRRs), as well as for cytokine secretion and bacterial clearance. When a broad range of PRRs is stimulated, including NOD2, TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9, INAVA associates with YWHAQ (14-3-3T). This leads to the recruitment and activation of MAP kinase and NF-kappa-B signalling complexes, which amplify PRR-induced downstream signals and cytokine secretion.
In the intestine, INAVA regulates the stability of adherens junctions. It does so by controlling the degradation of CYTH1 and CYTH2, probably acting as a substrate cofactor for SCF E3 ubiquitin-protein ligase complexes. By limiting CYTH1-dependent ARF6 activation, INAVA stabilises these junctions. The protein is located in the nucleus and cytoplasm, and NCBI Gene places it in the cytoplasm and nuclear bodies. Its roles include the NOD2 signalling pathway, positive regulation of cytokine production and positive regulation of intracellular signal transduction.
The INAVA gene was formerly called chromosome 1 open reading frame 106 (C1orf106), and FLJ10901 is also listed as an alias. The gene is implicated in inflammatory bowel disease 29, which makes the INAVA protein a useful subject for studies linking innate immune signalling to epithelial barrier function. A mouse ortholog, Inava, is recognised.
INAVA amplifies signalling downstream of NOD2 and several Toll-like receptors, so it is relevant to studies of PRR-driven MAP kinase and NF-kappa-B activation.
The protein is required for optimal cytokine secretion by macrophages and supports positive regulation of cytokine production.
INAVA stabilises adherens junctions by limiting CYTH1-dependent ARF6 activation, linking it to epithelial integrity in the intestine.
INAVA is implicated in inflammatory bowel disease 29, making it a focus for research on genetic contributions to intestinal inflammation.
INAVA is required for optimal PRR-induced signalling, cytokine secretion and bacterial clearance in macrophages and intestinal myeloid cells. It associates with YWHAQ to promote MAP kinase and NF-kappa-B activation. In the intestine it also stabilises adherens junctions by limiting CYTH1-dependent ARF6 activation.
INAVA stands for innate immunity activator. Its previous gene symbol was C1orf106, from the former name chromosome 1 open reading frame 106, and FLJ10901 is also listed as an alias. UniProt names the protein innate immunity activator protein.
NCBI Gene reports that INAVA is implicated in inflammatory bowel disease 29. The mouse ortholog is called Inava. Check the datasheet of any product for its validated reactivity.
Pattern recognition receptors, signalling partners and junction-regulating proteins that connect to INAVA biology.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q3KP66; product specifications from Assay Genie datasheets.